The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
|
|---|---|
| Published in |
Frontiers in oncology, June 2018
|
| DOI | 10.3389/fonc.2018.00163 |
| Pubmed ID | |
| Authors |
Timothy M. Pierpont, Candice B. Limper, Kristy L. Richards |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 29% |
| United States | 1 | 14% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Science communicators (journalists, bloggers, editors) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 594 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 594 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 96 | 16% |
| Student > Ph. D. Student | 72 | 12% |
| Student > Master | 70 | 12% |
| Researcher | 49 | 8% |
| Other | 35 | 6% |
| Other | 62 | 10% |
| Unknown | 210 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 99 | 17% |
| Medicine and Dentistry | 93 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 43 | 7% |
| Immunology and Microbiology | 38 | 6% |
| Agricultural and Biological Sciences | 37 | 6% |
| Other | 66 | 11% |
| Unknown | 218 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2022.
All research outputs
#1,859,868
of 25,837,817 outputs
Outputs from Frontiers in oncology
#372
of 22,773 outputs
Outputs of similar age
#38,009
of 345,009 outputs
Outputs of similar age from Frontiers in oncology
#12
of 151 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,773 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,009 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 151 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.